Results 81 to 90 of about 1,804,185 (380)
Intracellular Antibody Neutralizes Listeria Growth [PDF]
Immunity, 2001 We previously reported that treatment of mice with a neutralizing mAb against listeriolysin O (LLO), the pore-forming toxin of Listeria monocytogenes, provided resistance to this intracellular bacterium. We evaluated whether anti-LLO mAb would affect Listeria handling by macrophages, essential cells in Listeria resistance.
Emil R. Unanue, Brian T. Edelson
openaire +2 more sources
FEBS Letters, EarlyView.Mutations in the C9orf72 gene represent the most common genetic cause of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. Using patient‐derived neurons and C. elegans models, we find that the nucleoporin Nup107 is dysregulated in C9orf72‐associated ALS. Conversely, reducing Nup107 levels mitigates disease‐related changes.
Saygın Bilican +7 more
wiley +1 more source
Characterization of rubella-specific humoral immunity following two doses of MMR vaccine using proteome microarray technology. [PDF]
PLoS ONE, 2017 The lack of standardization of the currently used commercial anti-rubella IgG antibody assays leads to frequent misinterpretation of results for samples with low/equivocal antibody concentration.
Iana H Haralambieva +6 more
doaj +1 more source
Microbiology Spectrum, 2022 The neutralizing antibody response is a key component of adaptive immunity and a primary protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
Chloé Dimeglio +6 more
doaj +1 more source
The Role of Follicular Dendritic Cells in Human Immunodeficiency Virus Pathogenesis [PDF]
, 1995 Infection with Human Immunodeficiency Virus-1(HIV) results in a disease process characterized by three stages: an acute phase characterized by viremia, a clinically latent stage with little or no detection of virus in the blood, and the last stage, AIDS,
Heath, Sonya Lynn
core +1 more source
JAMA Internal Medicine, 2020 Key Points Question Are clinical characteristics of patients who recovered from mild coronavirus disease 2019 (COVID-19) associated with levels of neutralizing antibodies?
Fan Wu +18 more
semanticscholar +1 more source
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
npj Vaccines, 2021 Neutralizing antibody responses of SARS-CoV-2-infected patients may be low and of short duration. We propose here that coronaviruses employ a structural strategy to avoid strong and enduring antibody responses. Other viruses induce optimal and long-lived
M. Bachmann +4 more
semanticscholar +1 more source
Neutralizing antibodies for the treatment of COVID-19 [PDF]
Nature Biomedical Engineering, 2020 More clinical trial data are needed to determine whether sera from COVID-19-convalescent patients and neutralizing monoclonal antibodies specific to SARS-CoV-2 antigens can prevent COVID-19 or reduce the severity of the disease in high-risk populations.
Yang Yang +6 more
openaire +3 more sources
Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1
FEBS Letters, EarlyView.Vacor, a compound converted into the toxic metabolite Vacor adenine dinucleotide (VAD) by the nicotinamide salvage pathway enzymes NAMPT and NMNAT2, exhibits antitumor activity by inducing rapid and complete NAD depletion. We report that Vacor toxicity is limited to cell lines expressing high levels of SARM1, a NAD glycohydrolase.
Giuseppe Ranieri +5 more
wiley +1 more source
Cell Reports, 2016 A major step toward an HIV-1 vaccine is an immunogen capable of inducing neutralizing antibodies. Envelope glycoprotein (Env) mimetics, such as the NFL and SOSIP designs, generate native-like, well-ordered trimers and elicit tier 2 homologous ...
Jidnyasa Ingale +6 more
doaj +1 more source